Sanofi Global Health launches nonprofit Impact® brand for 30 medicines in low-income countries
04 July 2022 - 8:00PM
Sanofi Global Health launches nonprofit Impact®
brand for 30 medicines in low-income countries
- Medicines, including insulin, to be
available in 40 lower-income countries
- Investment fund established to help
create sustainable health systems
- Announcements comes as Global Health
stakeholders gather in Paris
Paris
– July
4, 2022 –
Sanofi Global Health
announces the
launch of
Impact®,
a new brand
of standard of care medicines produced
by Sanofi dedicated
for nonprofit distribution to
at-risk populations in the
world’s most impoverished
countries.
The Impact®
brand, which includes insulin, glibenclamide and
oxaliplatin amonst others, will enable the secure
distribution of 30 Sanofi
medicines in 40
lower-income countries.
Considered essential by the World Health Organization, the
medicines cover a wide range of therapeutic areas, including
diabetes, cardiovascular disease, tuberculosis, malaria and
cancer.
The launch of the Impact® brand is among the
steps taken since the formation last year of Sanofi Global Health,
a nonprofit unit within the company aiming to increase access to
healthcare through the distribution of medicines, and the building
and bolstering of local healthcare systems in countries with among
the lowest per capita GDP. Sanofi Global Health
is the first and
only global initiative to provide
access to such a broad portfolio of medicines in
so many countries and across multiple therapeutic
areas while funding local support
programs and strengthening local inclusive businesses.
Paul HudsonChief Executive
Officer, Sanofi“At Sanofi, we believe we have a responsibility to
make a difference for the health of those most in need, and we know
we have the ability and the ambition to bring about lasting change.
With critical medicines, relentless drive and impactful
partnerships, we can take our innovation beyond the lab and use it
to strengthen health systems and access to medicines for those most
vulnerable communities of patients. Sanofi Global Health aims to
improve the lives of millions of people who now cannot get the help
they need. Sanofi’s renewed purpose is to chase the miracles of
science to improve people’s lives. And our quest to make life
better for all people must include helping to provide better access
to care and quality medicines for underserved populations.”
The company also announces the establishment of
an Impact fund
that will support startup companies and
other innovators that can deliver scalable solutions for
sustainable healthcare in underserved regions. By
providing inclusive businesses
financing and technical assistance, the
fund will complement the GHU mission of
leveraging global, regional and local
investment to support
the training of
healthcare professionals and
aiding
communities in running
sustainable care systems. The announcements come
as Sanofi gathers key global health stakeholders to discuss how to
build effective end-to-end health programs that are embedded in the
communities in which they serve, to best reach, treat and manage
patients’ health effectively and sustainably.
Jon FairestHead, Global Health
Unit, Sanofi“The launch of the Impact® brand and our Impact Fund
are our latest steps to make our medicines available and to help
bring quality, sustainable healthcare to people in the world’s
poorest countries. But we know that we cannot do this alone, and so
we are building partnerships at global, regional and local levels
that will help to improve and establish health systems to reach our
goal of a healthier, more resilient world.”
Sanofi Global Health is one of the three
elements of Sanofi’s multi-tiered approach to Social impact, which
includes the Foundation S – the Sanofi
collective dedicated to philanthropy and
a Corporate
Social
Responsibility
strategy embedded in
our business
activities:
-
Foundation S is focused on efforts to fight
childhood cancer, increase the health resilience of populations
most affected by climate change, and provide donations of products
to meet humanitarian crises. Carrying on the company’s 30-year
legacy, Sanofi has also committed to
donating 100,000 vials
every year free of charge to support to patients with five
different lysosomal storage disorders (LSDs), a group of rare
genetic conditions caused by enzyme deficiencies.
- Our
company-wide CSR strategy focuses on four pillars:
affordable
access; innovation for
vulnerable communities; planet
care, in and beyond the workplace;
in addition to
responsible business. It is built around flagship
initiatives spread across the company’s value chain, from R&D
to manufacturing to commercial operations, considering every part
of the organization has a role to play and a contribution to
make.
About SanofiWe are an innovative global
healthcare company, driven by one purpose: we chase the miracles of
science to improve people’s lives. Our team, across some 100
countries, is dedicated to transforming the practice of medicine by
working to turn the impossible into the possible. We provide
potentially life-changing treatment options and life-saving vaccine
protection to millions of people globally, while putting
sustainability and social responsibility at the center of our
ambitions. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Media RelationsNicolas
Obrist | + 33 6 77 21 27 55
| nicolas.obrist@sanofi.comEvan Berland
| + 1 215 432 0234 | evan.berland@sanofi.com
Sanofi Investor RelationsEva
Schaefer-Jansen | + 33 7 86 80 56 39
| eva.schaefer-jansen@sanofi.comArnaud
Delépine | + 33 6 73 69 36 93 |
arnaud.delepine@sanofi.comCorentine
Driancourt | + 33 6 40 56 92 21 |
corentine.driancourt@sanofi.comFelix
Lauscher | + 1 908 612 7239 |
felix.lauscher@sanofi.comPriya
Nanduri | +1 617 764 6418 |
priya.nanduri@sanofi.com Nathalie
Pham | + 33 7 85 93 30 17 |
nathalie.pham@sanofi.com
Sanofi Forward-Looking
StatementsThis press release contains forward-looking
statements as defined in the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are statements
that are not historical facts. These statements include projections
and estimates regarding the marketing and other potential of the
product, or regarding potential future revenues from the product.
Forward-looking statements are generally identified by the words
"expects", "anticipates", "believes", "intends", "estimates",
"plans" and similar expressions. Although Sanofi's management
believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various
risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual
results and developments to differ materially from those expressed
in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other
things, unexpected regulatory actions or delays, or government
regulation generally, that could affect the availability or
commercial potential of the product, the fact that product may not
be commercially successful, the uncertainties inherent in research
and development, including future clinical data and analysis of
existing clinical data relating to the product, including post
marketing, unexpected safety, quality or manufacturing issues,
competition in general, risks associated with intellectual property
and any related future litigation and the ultimate outcome of such
litigation, and volatile economic and market conditions, and the
impact that COVID-19 will have on us, our customers, suppliers,
vendors, and other business partners, and the financial condition
of any one of them, as well as on our employees and on the global
economy as a whole. Any material effect of COVID-19 on any of the
foregoing could also adversely impact us. This situation is
changing rapidly and additional impacts may arise of which we are
not currently aware and may exacerbate other previously identified
risks. The risks and uncertainties also include the uncertainties
discussed or identified in the public filings with the SEC and the
AMF made by Sanofi, including those listed under "Risk Factors" and
"Cautionary Statement Regarding Forward-Looking Statements" in
Sanofi's annual report on Form 20-F for the year ended December 31,
2021. Other than as required by applicable law, Sanofi does not
undertake any obligation to update or revise any forward-looking
information or statements.
- PR Sanofi Global Health Unit 070422
Sanofi (EU:SAN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (EU:SAN)
Historical Stock Chart
From Apr 2023 to Apr 2024